Diabetes Drug Pricing Packaging 
Pharmaceutical Technology
JUNE 6, 2025
Find out more RTU cartridges are essential for storing glucagon-like peptide-1 drugs, biologics, insulin and hormone therapies used for treating diabetes, obesity and other immunological conditions. It will further extend the site’s manufacturing capabilities for high-value solutions.
Pharmaceutical Technology
JULY 4, 2025
This will largely be driven by the company’s glucagon like peptide-1 receptor agonist (GLP-1RA) tirzepatide, sold under the brand names Mounjaro and Zepbound for weight loss and type 2 diabetes respectively. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 21, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Fangzhou has signed a memorandum of understanding (MoU) with Novo Nordisk to collaborate on the management of serious chronic diseases including obesity and diabetes. GlobeNewswire.
Pharmaceutical Technology
JULY 25, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Reports LOA and PTSR Model - EBI-031 in Diabetic Macular Edema Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up!
STAT
OCTOBER 10, 2024
billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.
STAT
OCTOBER 17, 2024
billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines. Continue to STAT+ to read the full story…
BioPharma Dive
JUNE 23, 2025
Originally developed in the 1970s to treat diabetes, these drugs—such as Ozempic, Wegovy, and Mounjaro—have become headline-makers for their ability to induce significant weight loss. Understanding GLP-1 drugs GLP-1, or glucagon-like peptide-1 receptor modulators, mimic natural hormones that regulate insulin and appetite.
Expert insights. Personalized for you.
Let's personalize your content